PALISADE BIO, INC. Operating Lease Right-of-Use Assets
PALISADE BIO, INC. (PALI) had Operating Lease Right-of-Use Assets of $0 as of 2025-12-31, per its 10-K filed 2026-03-20.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-03-20
- 2025-12-31: Operating Lease, Right-of-Use Asset $0.00.
- 2025-09-30: Operating Lease, Right-of-Use Asset $0.00.
- 2025-06-30: Operating Lease, Right-of-Use Asset $22.00K.
- 2025-03-31: Operating Lease, Right-of-Use Asset $53.00K.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-20 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 |
| 2025-06-30 | $22.00K 10-Q · filed 2025-08-11 |
| 2025-03-31 | $53.00K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $84.00K 10-K · filed 2026-03-20 |
| 2024-09-30 | $113.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $142.00K 10-Q · filed 2024-08-12 |
| 2024-03-31 | $170.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $198.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | $224.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $250.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $275.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $300.00K 10-K · filed 2024-03-26 |
| 2022-09-30 | $324.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $363.00K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $64.00K 10-Q · filed 2022-05-13 |
| 2021-12-31 | $109.00K 10-K · filed 2023-03-22 |
| 2021-09-30 | $153.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $195.00K 10-Q · filed 2021-08-23 |
| 2020-12-31 | $275.00K 10-K · filed 2022-03-17 |
| 2019-12-31 | $204.30K 10-K · filed 2021-03-22 |
| 2019-09-30 | $204.30K 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |